1 0

    FDA Exclusivity Summary for NDA 217225 Izervay (Avacincaptad Pegol Sodium)

    FDA Exclusivity Summary for NDA 217225 Izervay (Avacincaptad Pegol Sodium)

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: A copy of any “Exclusivity Summary” prepared for NDA 217225 for Izervay (avacincaptad pegol sodium) approved on August 4, 2023.
    Tags: Pharma, NDA, 2023
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details